Hyung‐Don Kim

机构：Twitter (United States), University of Ulsan · ORCID：0000-0001-9959-0642

发表论文 154 篇 · 总被引 2962 次 · h-index 25

代表论文

• Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (2025 · Journal of Hepatology · 被引 18)
• Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy (2025 · Gastric Cancer · 被引 9)
• Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer (2025 · Cancer Immunology Immunotherapy · 被引 9)
• Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer (2025 · Journal for ImmunoTherapy of Cancer · 被引 9)
• Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer (2025 · Gastric Cancer · 被引 8)
• TCR signaling via NFATc1 constrains IL-15-induced bystander activation of human memory CD8+ T cells (2025 · Immunity · 被引 6)